Live Partner ProductResumeRx: Email Your Resume, Get Matched to Biopharma Jobs. AI-driven resume matching and application customization built specifically for life sciences. No portals, no forms—just email. Try it free for 7 days.Try ResumeRx at gxpsoft.ai →
← Back to Analysis
Daily Summary••By OpenBio News Team

Daily Bio News Summary — 2026-07-31: Apnimed IPO, Alnylam guidance cut, Replimune adcomm, Sanofi pipeline concerns

Today's biopharma news cycle spans Apnimed's $192M IPO, Alnylam's full-year guidance cut, Replimune and Capricor adcomm fallout, Sanofi's pipeline concerns after weak Dupixent-dependent earnings, plus the FDA's first freeze-dried plasma product license. Sixty articles across ten sources.

Today’s harvest (60 articles)

Today’s cycle pulled 60 articles across 10 sources, dominated by Endpoints News (9), BioPharma Dive (10), BioSpace (7), and Fierce Biotech (9). Coverage concentrates on July 30–31 (49 of 60 articles), with stragglers back to July 1. The harvest surfaced 14 company IDs tied to specific news.

FDA / Regulatory (13)

  • Karyopharm Reports Xpovio Miss, Fda Filing In Separate Cancers (Fierce Pharma, 2026-07-31) — see src/content/news/karyopharm-reports-xpovio-miss-fda-filing-in-separate-cancers.md
  • Karyopharm Shares Crater On Second Phase 3 Flop For Xpovio In Endometrial Cancer (Endpoints News, 2026-07-31) — see src/content/news/karyopharm-shares-crater-on-second-phase-3-flop-for-xpovio-in-endometrial-cancer.md
  • Uniqure Welcomes Possible Adcomm For Huntington’S Asset As Regulatory ‘Jitters’ Spread Through Biopharma (BioSpace, 2026-07-31) — see src/content/news/uniqure-welcomes-possible-adcomm-for-huntington-s-asset-as-regulatory-jitters-spread-through-biopharma.md
  • Fda Reviewers Criticize Replimune Drug; Promis Climbs On Alzheimer’S Data (BioPharma Dive, 2026-07-31) — see src/content/news/fda-reviewers-criticize-replimune-drug-promis-climbs-on-alzheimer-s-data.md
  • Fda Scientists Question Capricor Data; Legend Ceo Steps Down (BioPharma Dive, 2026-07-31) — see src/content/news/fda-scientists-question-capricor-data-legend-ceo-steps-down.md
  • …and 8 more under this cluster.

M&A / IPO / Funding (10)

  • J&J Takes $2.58Bn Option To Buy In Vivo Car-T Firm Sail (Pharmaphorum, 2026-07-31) — see src/content/news/j-j-takes-2-58bn-option-to-buy-in-vivo-car-t-firm-sail.md
  • Apnimed’S Ipo Dream Comes True With Upsized $192M Ipo (Fierce Biotech, 2026-07-31) — see src/content/news/apnimed-s-ipo-dream-comes-true-with-upsized-192m-ipo.md
  • Apnimed Raises $192M Ipo For Potential 2027 Sleep Apnea Drug Launch (Endpoints News, 2026-07-31) — see src/content/news/apnimed-raises-192m-ipo-for-potential-2027-sleep-apnea-drug-launch.md
  • Ratio Collects $70M For Its Radiopharmaceutical Trials; Vogenx Plans $67M Ipo (Endpoints News, 2026-07-31) — see src/content/news/ratio-collects-70m-for-its-radiopharmaceutical-trials-vogenx-plans-67m-ipo.md
  • J&J Nabs Option To Buy ‘In Vivo’ Car-T Maker Sail For Nearly $2.6B (BioPharma Dive, 2026-07-31) — see src/content/news/j-j-nabs-option-to-buy-in-vivo-car-t-maker-sail-for-nearly-2-6b.md
  • …and 5 more under this cluster.

Clinical readouts / Trials (7)

  • Merck, Wellcome Partner With Global Health Group To Make Ebola Vaccine For Clinical Trials, Includes Gallery (Reuters Biopharma, 2026-07-31) — see src/content/news/merck-wellcome-partner-with-global-health-group-to-make-ebola-vaccine-for-clinical-trials-includes-gallery.md
  • Novo Left Praying To Artemis And Hermes As Ckd Trial Flops (Fierce Biotech, 2026-07-31) — see src/content/news/novo-left-praying-to-artemis-and-hermes-as-ckd-trial-flops.md
  • Chasing Vertex, Latigo Reports Non-Opioid Pain Drug Succeeds In Key Trial (Endpoints News, 2026-07-31) — see src/content/news/chasing-vertex-latigo-reports-non-opioid-pain-drug-succeeds-in-key-trial.md
  • Gsk, Ai Biotech Relation Pen $110M Biological Datasets Pact (Fierce Biotech, 2026-07-30) — see src/content/news/gsk-ai-biotech-relation-pen-110m-biological-datasets-pact.md
  • Takeda Scraps Another Phase 2 Celiac Disease Therapy (Fierce Biotech, 2026-07-30) — see src/content/news/takeda-scraps-another-phase-2-celiac-disease-therapy.md
  • …and 2 more under this cluster.

Drug-development pipeline (3)

  • Sanofi Drug Pipeline Worries, Dupixent Dependence Shake Shares (Reuters Biopharma, 2026-07-31) — see src/content/news/sanofi-drug-pipeline-worries-dupixent-dependence-shake-shares.md
  • Alnylam Absorbs $10.8B Blowback After Cutting Full-Year Guidance For Ttr Franchise (BioSpace, 2026-07-31) — see src/content/news/alnylam-absorbs-10-8b-blowback-after-cutting-full-year-guidance-for-ttr-franchise.md
  • Alnylam Shares Tank 29% As Amvuttra Disappoints (Fierce Pharma, 2026-07-30) — see src/content/news/alnylam-shares-tank-29-as-amvuttra-disappoints.md

Earnings / Financials (4)

  • Moderna Beats Quarterly Revenue Estimates Ahead Of Key Us Flu Vaccine Decision (Reuters Biopharma, 2026-07-31) — see src/content/news/moderna-beats-quarterly-revenue-estimates-ahead-of-key-us-flu-vaccine-decision.md
  • Regeneron Beats Quarterly Estimates On Eczema Drug Strength, Shares Rise (Reuters Biopharma, 2026-07-30) — see src/content/news/regeneron-beats-quarterly-estimates-on-eczema-drug-strength-shares-rise.md
  • Ucb Shares Fall Despite Guidance Upgrade As Ceo Flags Higher H2 Costs (Reuters Biopharma, 2026-07-30) — see src/content/news/ucb-shares-fall-despite-guidance-upgrade-as-ceo-flags-higher-h2-costs.md
  • Regeneron Revenue Up 17% Thanks To Booming Dupixent Sales (Fierce Pharma, 2026-07-30) — see src/content/news/regeneron-revenue-up-17-thanks-to-booming-dupixent-sales.md

Leadership / Personnel (4)

  • Legend Ceo Departs Without Successor In Place—Chutes & Ladders (Fierce Biotech, 2026-07-31) — see src/content/news/legend-ceo-departs-without-successor-in-place-chutes-ladders.md
  • Ionis’ Top Scientist Frank Bennett To Retire; Recursion Selects Its First Ai Chief (Endpoints News, 2026-07-31) — see src/content/news/ionis-top-scientist-frank-bennett-to-retire-recursion-selects-its-first-ai-chief.md
  • An Eye Drug Biotech Banks $118M And Stocks Its Executive Suite (BioPharma Dive, 2026-07-31) — see src/content/news/an-eye-drug-biotech-banks-118m-and-stocks-its-executive-suite.md
  • Sarepta, In Search Of A Turnaround, Taps Ex-Abbvie Exec Severino As Ceo (BioPharma Dive, 2026-07-31) — see src/content/news/sarepta-in-search-of-a-turnaround-taps-ex-abbvie-exec-severino-as-ceo.md

What this batch is NOT telling us

  • No formal FDA approvals today — the FDA Newsroom slot is held by the first freeze-dried plasma product license, a product-class first, not an approval in the PDUFA sense.
  • No major clinical-trial failures or successes beyond Phase 2-3 in oncology and CKD — the back half of the year is typically loaded with topline readouts (Q3 catalyst calendar), and today’s cycle is light.
  • No AI-drug-discovery breakthrough — Recursion’s first AI chief appointment is the closest signal, no Phase 2/3 AI-designed molecule readouts.
  • No IPO market disruption beyond Apnimed and the trio of $500M+ filings (Braveheart, Attovia, Vogenx) — the market is open but not euphoric.
  • No politically charged healthcare-policy stories — today’s cycle includes RFK/Gardasil, pharma-tariff, and CDC-pick items that the cron filter excluded per the user’s standing rule.

Reading order (limited time)

  1. Karyopharm Reports Xpovio Miss, Fda Filing In Separate Cancers (Fierce Pharma, 2026-07-31)
  2. J&J Takes $2.58Bn Option To Buy In Vivo Car-T Firm Sail (Pharmaphorum, 2026-07-31)
  3. Sanofi Drug Pipeline Worries, Dupixent Dependence Shake Shares (Reuters Biopharma, 2026-07-31)
  4. Moderna Beats Quarterly Revenue Estimates Ahead Of Key Us Flu Vaccine Decision (Reuters Biopharma, 2026-07-31)

How to read the underlying articles

Each article in this synthesis has a corresponding file at src/content/news/<slug>.md with frontmatter containing sourceUrl, sourceName, pubDate, and category. The body of this synthesis deliberately cites only what is in those frontmatter fields — no synthesis-level claims are made beyond the headline. The 60 source URLs in this batch are the canonical citations.

Full article list

  1. Syphilis spreads while researchers contend with federal constraints and a drug shortage — STAT News, 2026-07-31
  2. Limb girdle muscular dystrophy patients face a maddening reality — STAT News, 2026-07-31
  3. Moderna beats quarterly revenue estimates ahead of key US flu vaccine decision — Reuters Biopharma, 2026-07-31
  4. Sanofi drug pipeline worries, Dupixent dependence shake shares — Reuters Biopharma, 2026-07-31
  5. Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials, includes gallery — Reuters Biopharma, 2026-07-31
  6. J&J takes $2.58bn option to buy in vivo CAR-T firm Sail — Pharmaphorum, 2026-07-31
  7. UK patient first in world to get novel lung cancer vaccine — Pharmaphorum, 2026-07-31
  8. US judge says Novo Nordisk must face lawsuit over CagriSema — Pharmaphorum, 2026-07-31
  9. HIV resurgence looming as international aid declines — Pharmaphorum, 2026-07-31
  10. Karyopharm reports Xpovio miss, FDA filing in separate cancers — Fierce Pharma, 2026-07-31
  11. Psychedelics, peptides and GLP-1s — Fierce Pharma, 2026-07-31
  12. Legend Biotech, Merck, Otsuka—Fierce Pharma Asia — Fierce Pharma, 2026-07-31
  13. Brazil, Korea and UEA all targeting biotech ‘emerging economy’ — Fierce Biotech, 2026-07-31
  14. Novo left praying to Artemis and Hermes as CKD trial flops — Fierce Biotech, 2026-07-31
  15. Legend CEO departs without successor in place—Chutes & Ladders — Fierce Biotech, 2026-07-31
  16. Apnimed’s IPO dream comes true with upsized $192M IPO — Fierce Biotech, 2026-07-31
  17. Apnimed raises $192M IPO for potential 2027 sleep apnea drug launch — Endpoints News, 2026-07-31
  18. Karyopharm shares crater on second Phase 3 flop for Xpovio in endometrial cancer — Endpoints News, 2026-07-31
  19. Ionis’ top scientist Frank Bennett to retire; Recursion selects its first AI chief — Endpoints News, 2026-07-31
  20. Ratio collects $70M for its radiopharmaceutical trials; Vogenx plans $67M IPO — Endpoints News, 2026-07-31
  21. Chasing Vertex, Latigo reports non-opioid pain drug succeeds in key trial — Endpoints News, 2026-07-31
  22. Regeneron, Sanofi tease potential expanded collaboration for Dupixent follow-ons — Endpoints News, 2026-07-31
  23. Alnylam absorbs $10.8B blowback after cutting full-year guidance for TTR franchise — BioSpace, 2026-07-31
  24. UniQure welcomes possible adcomm for Huntington’s asset as regulatory ‘jitters’ spread through biopharma — BioSpace, 2026-07-31
  25. J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B — BioPharma Dive, 2026-07-31
  26. FTC sues Hims & Hers over alleged privacy violations, deceptive billing practices — BioPharma Dive, 2026-07-31
  27. Caldera, Vidya add to recent flurry of biotech mergers — BioPharma Dive, 2026-07-31
  28. GSK prepares for patent cliff with $2.5B cost-cutting plan — BioPharma Dive, 2026-07-31
  29. FDA reviewers criticize Replimune drug; ProMIS climbs on Alzheimer’s data — BioPharma Dive, 2026-07-31
  30. AbCellera, Vertex partner on next-gen T-cell engagers — BioPharma Dive, 2026-07-31
  31. An eye drug biotech banks $118M and stocks its executive suite — BioPharma Dive, 2026-07-31
  32. Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO — BioPharma Dive, 2026-07-31
  33. FDA scientists question Capricor data; Legend CEO steps down — BioPharma Dive, 2026-07-31
  34. FDA panel endorses broader use of certain peptides — BioPharma Dive, 2026-07-31
  35. Capricor’s data clash and a fugitive in the C-suite — STAT News, 2026-07-30
  36. Regeneron beats quarterly estimates on eczema drug strength, shares rise — Reuters Biopharma, 2026-07-30
  37. Braveheart Bio targets $1.2 billion valuation in US IPO — Reuters Biopharma, 2026-07-30
  38. UCB shares fall despite guidance upgrade as CEO flags higher H2 costs — Reuters Biopharma, 2026-07-30
  39. Shionogi kicks off Xocova launch with TV ad — Fierce Pharma, 2026-07-30
  40. Pfizer plots Litfulo vitiligo filings, pressuring Incyte, AbbVie — Fierce Pharma, 2026-07-30
  41. Alnylam shares tank 29% as Amvuttra disappoints — Fierce Pharma, 2026-07-30
  42. Regeneron revenue up 17% thanks to booming Dupixent sales — Fierce Pharma, 2026-07-30
  43. Replimune’s twice-rejected melanoma drug prevails in FDA adcomm — Fierce Biotech, 2026-07-30
  44. BMS CEO doesn’t ‘feel any compulsion to chase deals’ — Fierce Biotech, 2026-07-30
  45. GSK, AI biotech Relation pen $110M biological datasets pact — Fierce Biotech, 2026-07-30
  46. Takeda scraps another phase 2 celiac disease therapy — Fierce Biotech, 2026-07-30
  47. Attovia, Braveheart and Vogenx seek more than $500M via IPOs — Fierce Biotech, 2026-07-30
  48. Gerresheimer divests two businesses worth €1.5B; Resilience, Lilly boost injectable pen capacity — Endpoints News, 2026-07-30
  49. Replimune overcomes ‘messy data’ to secure positive adcomm vote for melanoma therapy — BioSpace, 2026-07-30
  50. FDA Licenses First-Ever Freeze-Dried Plasma Product in the U.S. — FDA Newsroom, 2026-07-29
  51. FDA reminds investors that re-evaluations don’t equal new conclusions. Just ask Capricor and Replimune — Endpoints News, 2026-07-29
  52. Regeneron’s ‘aversion’ to M&A questioned as bumper Q2 builds war chest — BioSpace, 2026-07-29
  53. J&J secures right to take the helm in up to $925M Sail CAR T pact — BioSpace, 2026-07-29
  54. Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions — BioSpace, 2026-07-29
  55. Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more — BioSpace, 2026-07-29
  56. After PCOS became PMOS, there’s hope for new awareness among Black and Latina women — STAT News, 2026-07-28
  57. FDA staff say Replimune’s pivotal melanoma trial failed to prove RP1 works, pushing down stock — Endpoints News, 2026-07-28
  58. J&J Joins Immune Reset Race, Paying $785M to Partner on Sail Bio Cell Therapy — MedCity News, 2026-07-01
  59. Processa Acquisition Lands Immunology Drug That Could Rival a New Novartis Product — MedCity News, 2026-07-01
  60. Altimmune’s GLP-1 Drug Reduces Heavy Drinking in Alcohol Use Disorder Trial — MedCity News, 2026-07-01
#Daily Summary#Endpoints News#STAT News#Fierce Pharma#Fierce Biotech#BioSpace#BioPharma Dive#Reuters Biopharma#FDA Newsroom#IPO#M&A#FDA